Prove safety and effectiveness as well as improvement in near visual acuity performance and increase in near visual acuity. 3 months [clinicaltrials_resource:6dfe2216c7a1d31eabb15bf81a8c6346]
Presbyopic patients, slightly hyperopes
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Prove safety and effectiveness as well as improvement in near visual acuity performance and increase in near visual acuity. 3 months [clinicaltrials_resource:6dfe2216c7a1d31eabb15bf81a8c6346]
Presbyopic patients, slightly hyperopes
Bio2RDF identifier
6dfe2216c7a1d31eabb15bf81a8c6346
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:6dfe2216c7a1d31eabb15bf81a8c6346
measure [clinicaltrials_vocabulary:measure]
Prove safety and effectiveness ...... ncrease in near visual acuity.
time frame [clinicaltrials_vocabulary:time-frame]
description
Presbyopic patients, slightly hyperopes
identifier
clinicaltrials_resource:6dfe2216c7a1d31eabb15bf81a8c6346
title
Prove safety and effectiveness ...... n near visual acuity. 3 months
@en
type
label
Prove safety and effectiveness ...... e2216c7a1d31eabb15bf81a8c6346]
@en